The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

Opinion
Video

Sai-Hong Ou, MD, PhD, discusses the rapidly evolving landscape of first-line therapy for sensitizing EGFR mutant non-small cell lung cancer, including potential combination therapies and the introduction of new treatment options, such as antibody drug conjugates.

Recent Videos
4 experts in this video
4 experts in this video
5 experts in this video
4 experts in this video
5 experts in this video
4 experts in this video
Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.
A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.
5 experts in this video
5 experts in this video
Related Content